1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Antibody Technologies and Attrition Rates – an industry analysis 2013

  • March 2013
  • 607 pages
  • La Merie Publishing
Report ID: 1154426

Summary

Table of Contents

Search Inside

Product Description

The report “Antibody Technologies and Attrition Rates – an industry analysis 2013” is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013. The antibodies are categorized as active during the study period or discontinued during or before the study period. Attrition rates were calculated across a number of variables.

Descriptive statistics of the 504 naked antibodies include the following variables:

• Unique antibody identifiers (drug codes; generic name; brand name)
• Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
• In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
• In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse, • • HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
• Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
• Antibody status (active/discontinued)
• Year of failure
• Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
• Target
• Immunoglobulin class and IgG isotype
• Highest phase
• Therapeutic area of lead indication
• Companies (developer, licensor/originator)

An Antibody Data Sheet was prepared for each unique antibody containing the retrieved information and the source of information in the form of a scientific reference or a hyperlink leading to the website from which the information was obtained.

The analysis essentially evaluated the question whether there are differences in clinical attrition rates between in vitro and in vivo antibody generation technologies as well as within the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive antibodies.

Benefits from the data and the analysis:

• Understand the historical and present state of the art use of antibody technologies;
• Learn the success rate of each antibody generation technology;
• Understand the reasons for failure of antibodies in clinical development;
• Appreciate the relative value of generic and of IP protected antibody technologies;
• Know which antibody technologies are using your competitors;
• Know the preferred antibody formats, IgG isotypes, development indications, parental wild-type animal species.
• Learn the influence of the target for the success rate of the selected antibody technology.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Biosimilars Market-Growth, Trends & Forecasts. (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The Global Biosimilars Market was valued at USD 5237.0 currently and is projected to reach USD 28200.0 million by 2020, at a CAGR of 40.3% during the forecast period from 2015 to 2021. The global biosimilars ...

Biosimilars Market Access in the U.S.

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

The route to a formal US regulatory pathway for biosimilar approval was established with the creation of the Biologics Price Competition and Innovation Act of 2010. However, it took five more years fo ...

Biosimilars Market Access in Psoriasis

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.